after signing the informed consent, the patient becomes a participant in the study that investigates treatments for metastatic cervical cancer.

the patient undergoes a series of examinations that include medical history, physical examination, laboratory tests, and imaging studies to document the extent of disease before any study medication is given.

on the day scheduled for the first dose, the patient receives two intravenous infusions:

avastin (bevacizumab) at a dose of 15 mg per kilogram of body weight, administered as an infusion into a vein,

and keytruda (pembrolizumab) at a fixed dose of 400 mg, also given as an intravenous infusion.

the patient returns for additional infusion visits according to the study schedule; at each visit the same doses of avastin and keytruda are administered intravenously.

treatment continues until disease progression, unacceptable side effects, or until the end of the study period as defined by the protocol.

at each infusion visit and at predefined intervals, the patient receives clinical assessments, laboratory tests, and imaging to detect any adverse effects or changes in health status.

the study measures progression‑free survival, which is the time from the start of the first treatment to the first documented disease progression or death.

specific evaluations are performed at 12 months and 24 months to determine whether the patient remains free of disease progression.

when the study ends or the patient discontinues treatment, a final assessment is performed to record the overall outcome, including any lasting effects of the medications.